Migwax, the company established for the purpose of commercializing the patent, says that the animal experiment that ended gave promising results. Clinical trials in humans will begin immediately after raising additional funding for the company
MigVax Ltd., a start-up company developing an oral vaccine (administered orally) of the subunit type, against the corona virus COVID-19, announced promising results from pre-clinical trials that proved the effectiveness of the oral vaccine as a booster vaccine for previously vaccinated people.
In the experiment, tests were conducted on rats that demonstrated that the oral oral vaccine of MigVax-101 as a boost vaccine after the administration of a vaccine based on the injected S1 protein, resulted in an increase in neutralizing antibodies significantly more than rats that received an oral placebo booster. Additionally, similar to a third booster shot, it elicited more effective neutralizing antibodies.
MigVax is currently raising the necessary funding to start phase 1 and 2 clinical trials, which will lead to commercial availability 9-12 months after the start of the trials. The full results of the preclinical testing were published in a scientific journal.
The oral vaccine, through the mouth, Mig-Vax-101 offers significant potential advantages compared to the existing injected vaccines and as a booster:
• Oral administration eliminates the need for administration by health professionals.
• The RBD subunit protein in the vaccine can be quickly adapted to new mutations of the virus, in order to produce more effective neutralizing antibodies. In addition, because the other components of the vaccine are composed of a protein that is not prone to change, the vaccine may remain effective for longer periods before needing a booster.
• Mucosal immunity: preclinical data showed an increased presence of mucosal IgA, indicating that the oral vaccine provides unique protection where the virus enters the body.
• Ease of transportation and storage: while MigVax-101 does require refrigeration, it does not require "deep freezing" conditions, thus significantly reducing distribution and storage and logistics costs.
• Applicability to a wider population: since a vaccine is given orally, is not injected and does not contain viruses, or genetic material, it will be suitable for a wider population, including those who are reluctant to receive an injected vaccine of genetic or viral material as well as for infants, children, pregnant women and other segments of the population .
Prof. Itamar Shalit, infectious disease specialist and MigVax consultant. Says: "The results of this trial increase our confidence that an oral oral vaccine, Mig-Vax-101, will make a positive contribution to the world facing the new post-pandemic reality. 101 months into the pandemic, we now see that the fight to control the corona virus is challenging. An oral booster vaccine like our MigVax-15 will help healthcare organizations around the world move from 'panic to routine' due to their ability to reduce cost and expand reach to many countries around the world."
MigVax-101 is an innovative vaccine administered orally in liquid or capsule and contains three chimeric proteins, in order to create three types of immune responses simultaneously: immunity in the mucosal system, immunity in the immune system and immunity in the cellular system. This triple approach provides comprehensive protection against the corona virus by activating all arms of the immune system, and enables effective eradication of the invading virus. Its epitopes were designed using computational chemistry of immunogenic epitopes in SARS-COV-2 with a focus on neutralizing antibodies and promoting an immune response.
MigVax was established by the Miguel Research Institute in the Galilee. The institute previously developed an oral vaccine against the infectious bronchitis virus, a strain of the corona virus that causes the bronchial disease that affects poultry. The effectiveness of the poultry vaccine was proven in experiments on animals carried out at the Veterinary Institute in Israel. MigVax is using methods learned from the avian vaccine to develop a new human vaccine for COVID-19. The first round of investments in the company was led by OurCrowd, a global risk investment platform that enables institutions and individuals to invest and engage in developing companies.
More of the topic in Hayadan:
3 תגובות
If so I apologize. This is not about financial interest but bad press.
The science service is not another name for advertising. We didn't get a penny
This is already crossing the line.
You write, apparently without checking, what commercial stakeholders tell you. You write "the full results of the pre-clinical test were published in a scientific journal" but do not bother to mention the disclaimer that appears on the same website:
bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.
In other words: the study was not peer-reviewed.
At least be decent and explicitly explain to your readers that the "Knowledge Service" section is an advertisement section. A little more respect for your readers is more important than a few shekels you manage to earn here and there at the expense of your reputation.